According to filings with the U.S. Securities and Exchange Commission, Harpoon Therapeutics is raising $100,162,467.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Julie Eastland played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoons first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

To learn more about Harpoon Therapeutics, visit http://www.harpoontx.com/

Contact:
Julie Eastland, President and Chief Executive Officer
650-443-7400

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.